Literature DB >> 9400760

A multivariate analysis of anatomic success of recurrent retinal detachment treated with pneumatic retinopexy.

T Sharma1, S S Badrinath, B N Mukesh, L Gopal, M P Shanmugam, P Bhende, M Bhende, N S Shetty, R Agrawal.   

Abstract

PURPOSE: The purpose of the study is to determine the success rate of pneumatic retinopexy (PR) after failed scleral buckling and to elucidate the predictors for anatomic failure by multiple logistic regression analysis.
METHODS: Thirty-six eyes with recurrent retinal detachment after failed scleral buckling underwent PR. Intraocular tamponade was attained with SF6 (20 eyes), C3F8 (13 eyes), and air (3 eyes). Median follow-up was 14 months.
RESULTS: Retinal reattachment was obtained in 69.4%. Multivariate analysis identified two risk factors for failure: location of retinal break either on the posterior slope or posterior to buckle (P = 0.01) and extent of retinal detachment greater than two quadrants (P = 0.02).
CONCLUSIONS: Pneumatic retinopexy is an effective alternative to revision surgical operations if the leaking retinal break is located on the buckle.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9400760     DOI: 10.1016/s0161-6420(97)30063-3

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  3 in total

1.  An analysis of the outcomes for patients with failed primary vitrectomy for rhegmatogenous retinal detachment.

Authors:  Edward Lee; Zine El Housseini; D H W Steel; Tom H Williamson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-26       Impact factor: 3.117

2.  Pneumatic retinopexy: A cost-effective alternative.

Authors:  Ritesh Narula
Journal:  Indian J Ophthalmol       Date:  2018-03       Impact factor: 1.848

3.  Pneumatic retinopexy outcomes as primary or secondary surgical option for treating rhegmatogenous retinal detachment.

Authors:  Abhinav Dhami; Kunal Kaushik Shah; Dhanashree Ratra
Journal:  Indian J Ophthalmol       Date:  2018-03       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.